• Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • NOXAFIL delayed-release tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia (low white blood cell counts) from chemotherapy. (careerhospital.com)
  • Prophylaxis against invasive Aspergillus and Candida infections plays a key role in the management of severely immunocompromised patients with hematologic malignancies or hematopoietic stem cell transplant recipients who are at high risk for these life-threatening fungal infections," said Daniel Couriel, M.D., professor of internal medicine and clinical program director, adult blood and marrow transplantation program, University of Michigan Comprehensive Cancer Center. (careerhospital.com)
  • Attention and working memory (WM) findings in pediatric patients prior to hematopoietic stem cell transplant (HSCT) for hematologic malignancies. (upenn.edu)
  • Rob Soiffer, MD is currently Chief of the Division of Hematologic Malignancies and Co-Director of the Adult Stem Cell Transplantation Program at the Dana-Farber Cancer Institute. (vorbio.com)
  • a broad range of disorders for which transplantion of HPCs from an adult donor is also successful, including hematological malignancies, solid tumors, constitutional and acquired bone marrow failure syndromes, hemoglobinopathies, congenital immune deficiencies, and inherited disorders of metabolism (Gluckman et al. (nationalacademies.org)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • On April 17, 2023, the FDA approved omidubicel-onlv, brand name Omisirge, for use in adult and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection. (fda.gov)
  • Blood and Marrow Transplant Research [CIBMTR] in 2004), the European Research Project on Cord Blood Transplantation (Eurocord) in 1993, and the Japanese Cord Blood Banking Network in 1996-expedited the clinical evaluation of the efficacy and safety of transplantation of cord blood from unrelated donors. (nationalacademies.org)
  • SideriA, Neokelous N, de la Grange PB, Guerton B, Lee BousseKerdilles MC, Uzan G, Peste-Tsilimidos C, and Gluckman E. An overview of the progress on double umbilical cord blood transplantation .Haematologica . (prostem.co.id)
  • One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers. (prostem.co.id)
  • Double Unit Grafts Successfully Extend The Aplication Of Umbilical Cord Blood Transplantation in Adults With Acute Leukemia. (prostem.co.id)
  • Umbilical Cord Blood Transplantation for The Treatment of Hematologic Malignancies. (prostem.co.id)
  • Unrelated Donor Cord Blood Transplantation in Children: Lessons Learned Over 3 Decades. (mcw.edu)
  • The purpose of this study is to evaluate the effectiveness of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder. (mayo.edu)
  • The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy. (mayo.edu)
  • The primary objective of Phase 1 is to determine the recommended Phase 2 dose (RP2D) administered after infusion of αβdepleted-HSCT in children and young adults with hematologic malignancies. (stanford.edu)
  • URD TCRαβ/CD19-depleted peripheral HSCT is a safe and effective approach to transplantation for children/YAs with leukemia. (chop.edu)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • Initially, the program will offer consultative services (regarding donor selection, transplant eligibility and post-transplant follow-up) for people with a variety of hematologic malignancies as well as transplant procedures in select individuals. (lvhn.org)
  • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. (sagepub.com)
  • This webcast will discuss the emerging standards of care for transplantation for nonmalignant hematologic diseases, donor selection strategies that allow access for all patients who require a transplant, and the importance of follow-up care for prevention of complications that are unique to these populations. (optumhealtheducation.com)
  • Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options. (uchicago.edu)
  • Recent advances in the understanding of immunological mechanisms of GVHD have shown that activation of donor immune cells is tightly regulated by the microenvironment tissue or digestive microbiota changes after transplantation. (pasteur.fr)
  • Sixty pediatric and young adult (YA) patients with hematologic malignancies who lacked a matched-related donor were enrolled at 2 large pediatric transplantation centers between October 2014 and September 2019. (chop.edu)
  • He also has expertise with cellular therapies for hematologic malignancies, specifically chimeric antigen receptor (CAR) T-cell therapy. (lvhn.org)
  • She completed the American Society for Blood and Marrow Transplantation Clinical Research Training Course (2012). (wikipedia.org)
  • The main efficacy outcome measures were time to neutrophil recovery following transplantation and the incidence of Blood and Marrow Transplant Clinical Trials Network Grade 2/3 bacterial or Grade 3 fungal infections through Day 100 post transplantation. (fda.gov)
  • The incidence of Blood and Marrow Transplant Clinical Trials Network Grade 2/3 bacterial or Grade 3 fungal infections through Day 100 post transplantation was 39% and 60%, respectively, in the two groups. (fda.gov)
  • Search clinical trials for adult and pediatric cancers and blood disorders offered through Dana-Farber and our clinical partners. (dana-farber.org)
  • The Cellular Therapies Program team leads clinical care and research of promising cellular therapies across all adult disease centers. (dana-farber.org)
  • As the clinical nurse specialist on the adult inpatient transplant unit, I work with the nurse leader and clinical staff to promote a culture of excellence in the care of our patients. (mskcc.org)
  • Considering seasonal incidence of RSV-associated hospitalization among adults, stratified by age, incidence is substantially higher among adults aged 70-79 years and 80 years and older, compared with younger age groups. (cdc.gov)
  • Focusing on the potential age thresholds of interest, adults aged 60-64 years and 65-69 years both experience intermediate incidence of hospitalization, compared with that in adults 70 and older and younger adults. (cdc.gov)
  • 8 Over the surveillance years 2016-2020, CDC estimates that hospitalization incidence among adults 65 and older was approximately 2-fold to 3-fold higher than among adults 60-64. (cdc.gov)
  • Knowledge of areas where endemic mycosis incidence is increased may affect diagnostic or prevention measures for older adults at risk. (cdc.gov)
  • Hospitalization rates for adults were described per region, but incidence rates, specifically for older patients, were not available. (cdc.gov)
  • In contrast, patients with nonmalignant hematologic diseases such as sickle cell disease, congenital cytopenias, and immunodeficiencies have previously not been transplant-eligible, or receive the procedure only at an advanced disease stage. (optumhealtheducation.com)
  • Allogeneic hematopoietic stem cell (HSC) is a curative treatment used for many hematologic malignancies and congenital or acquired anomalies of hematopoiesis. (pasteur.fr)
  • She is a member of multiple societies, including the American Society of Hematology, the American Society for Transplantation and Cellular Therapy, the Children's Oncology Group, the Therapeutic Advances in Childhood Leukemia & Lymphoma consortium and the Pediatric Blood and Marrow Transplant Consortium. (wikipedia.org)
  • In addition to her work in leukemia, she also serves to support pediatric transplantation at the NCI by serving as an associate investigator on several transplant trials focused on patients with primary immunodeficiency and is leading the effort on transplantation for children with DOCK8 deficiency in collaboration with investigators in NIAID. (wikipedia.org)
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
  • Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. (sagepub.com)
  • AML is the most common acute leukemia in adults and current treatments are largely ineffective. (ca.gov)
  • Reduced Intensity Conditioned Allograft Yields Favorable Survival for Older Adults with B-cell Acute Lymphoblastic Leukemia. (stembook.org)
  • Four-year overall survival was 69% (95% confidence interval [CI], 52%-81%), and leukemia-free survival was 64% (95% CI, 48%-76%), with no difference between lymphoid and myeloid malignancies (P = .6297 and P = .5441, respectively). (chop.edu)
  • FDA approved quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (org.in)
  • DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. (mcw.edu)
  • On April 1, the U.S. Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta) for adult patients with large B-cell lymphoma (LBCL) who are refractory to first-line chemoimmunotherapy or who experienced relapse within 12 months of first-line chemoimmunotherapy. (ascopost.com)
  • FDA approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. (org.in)
  • During December 2017-October 2021, the ACIP Herpes Zoster Work Group participated in monthly or bimonthly teleconferences to review herpes zoster epidemiology and evidence for the efficacy and safety of RZV in immunocompromised adults. (cdc.gov)
  • Innovations in immunotherapy have led to the development of multiple immune-targeted therapies to manage malignancy. (ajmc.com)
  • She researches the translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults. (wikipedia.org)
  • Her primary research interests focus on translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults. (wikipedia.org)
  • Tailoring feedback sessions for young adults with cognitive difficulties: Case examples from oncology. (upenn.edu)
  • True aplastic anemia (most common in adolescents and young adults) is idiopathic in about half of cases. (msdmanuals.com)
  • We tested this novel hypothesis in over 6,000 HCT from 8/8 HLA-matched UD reported to the European Group for Blood and Marrow Transplantation (EBMT), to demonstrate that HLA-DPB1 non-TPHE mismatches were associated with worse relapse-free survival and overall survival than TPHE mismatches, present in 21.7% of single HLA-DPB1 disparate pairs. (haematologica.org)
  • Predictors of lost to follow-up among pediatric and adult hematopoietic cell transplant survivors: A report from the Center for International Blood and Marrow Transplant Research. (stembook.org)
  • Neurocognitive dysfunction in hematopoietic cell transplant recipients: Expert review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. (upenn.edu)
  • Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. (mcw.edu)
  • Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms, but can lead to severe outcomes, including hospitalization and death, especially for infants and older adults. (cdc.gov)
  • Safety and efficacy were evaluated in Study P0501, an open-label, multicenter, randomized trial of omidubicel-onlv transplantation or unmanipulated cord blood unit transplantation following myeloablative conditioning in patients with hematologic malignancies. (fda.gov)
  • In the last decade, the number of transplantations of HPCs derived from cord blood has increased, particularly for children. (nationalacademies.org)
  • 2003). After the early success of transplantation of cord blood from related donors, cord blood banks were established to provide rapidly accessible, human leukocyte antigen (HLA)-typed units predominantly for transplantation of HPCs from unrelated donors. (nationalacademies.org)
  • With more than 6,000 transplants of cord blood from related and unrelated donors performed thus far, cord blood has emerged as an acceptable, alternative source of HPCs that has some advantages over adult sources of HPCs and the availability of which represents an important development in the field. (nationalacademies.org)
  • In this project, the team of Dr. David Michonneau and Professor Gérard Socié (INSERM U976 / Saint Louis Hospital AP-HP / University of Paris) was interested in the study of the metabolome of allogeneic patients in the hospital Saint- Louis AP-HP in the hematology-transplant adult service. (pasteur.fr)
  • Refer to Recommendations for use, Adolescents and Adults for more information. (canada.ca)
  • For recommendations for individuals 6 months of age and older who are moderately to severely immunocompromised, refer to Children , Adolescents and Adults . (canada.ca)
  • A first booster dose of mRNA COVID-19 vaccine should be offered to adults 18 years of age and older and select children and adolescents 5 to 17 years of age. (canada.ca)
  • SCT is a standard treatment strategy for children and adults with refractory or relapsed hematologic malignancies. (optumhealtheducation.com)
  • MM is matological malignancies, which can be up characterized by monoclonal paraprotein to 75% in acute leukaemia. (who.int)
  • Compared with years past, older adults today are more likely to be considered for transplantation, receive aggressive regimens of chemotherapy, or take immunosuppressive drugs for rheumatologic or autoimmune diseases. (cdc.gov)
  • Increasing age and decreasing cell-mediated immunity as a result of transplantation, chemotherapy, or other immunosuppressive medications (e.g., tumor necrosis factor-α inhibitors) are the main predisposing factors ( 1 , 2 , 9 ). (cdc.gov)
  • The likelihood of developing hematologic malignancies also dramatically increases with age and is potentially driven by HSC dysfunction. (helmholtz-muenchen.de)
  • Dr. Toor is a renowned transplanter, and he is dedicated to determining the best treatment option for each individual based on their comorbidities and the genomics of their malignancy," says hematologist oncologist Suresh Nair, MD , Physician in Chief, Lehigh Valley Topper Cancer Institute. (lvhn.org)
  • On July 23, 2021, the Food and Drug Administration expanded the indication for use of recombinant zoster vaccine (RZV) to include immunodeficient or immunosuppressed adults. (cdc.gov)
  • On October 20, 2021, the Advisory Committee on Immunization Practices recommended 2 RZV doses for prevention of herpes zoster and related complications in immunodeficient or immunosuppressed adults aged ≥19 years. (cdc.gov)
  • On July 23, 2021, the FDA expanded the indication for recombinant zoster vaccine (RZV) to include adults aged ≥18 years who are or will be at increased risk for herpes zoster because of immunodeficiency or immunosuppression caused by known disease or therapy ( 2 ). (cdc.gov)
  • On October 20, 2021, ACIP recommended 2 doses of RZV for the prevention of herpes zoster and related complications in adults aged ≥19 years † who are or will be immunodeficient or immunosuppressed because of disease or therapy. (cdc.gov)
  • Further research is needed to establish the utility of CGA in predicting toxicity and to evaluate the quality of survival in older adults undergoing HCT. (nccn.org)
  • Since 1947, Dana-Farber's sole focus has been to provide expert cancer care and groundbreaking treatments for adult and pediatric patients. (dana-farber.org)
  • Given the high transplant-related morbidity, these treatment strategies were initially restricted to younger patients, but are increasingly being used in older adults. (nccn.org)
  • Here we review the data for the use of QuantiFERON-TB Gold In-Tube and T-SPOT.TB, the two currently available IGRAs, in immunocompromised adults, including persons infected with HIV, patients with immune-mediated inflammatory disorders, candidates for treatment with tumor necrosis factor-α inhibitors, patients receiving hemodialysis, solid-organ transplant recipients, and patients with cancer. (atsjournals.org)
  • The overall goal has been the development of improved treatment approaches for patients with genetic and infectious diseases and cancer, in particular, hematologic malignancies. (vorbio.com)
  • On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. (asco.org)
  • FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia. (org.in)
  • FDA Approves Bristol Myers Squibb's Reblozyl ( luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions. (org.in)
  • The research of Hans-Peter Kiem, MD, PhD has focused on stem cell and transplantation biology, cell and gene therapy, and the development and use of novel gene-editing technologies. (vorbio.com)
  • Nirali N. Shah is an American physician-scientist and pediatric hematologist-oncologist, serving as head of the hematologic malignancies section of the pediatric oncology branch at the National Cancer Institute. (wikipedia.org)
  • Shah is a physician-scientist who serves as the head of the hematologic malignancies section of the Pediatric Oncology Branch. (wikipedia.org)
  • It is estimated that 25% to 40% of patients with HIV infection will develop a malignancy and approximately 10% will develop NHL. (medscape.com)
  • For infections such as histoplasmosis or blastomycosis, much of the information regarding geographic distribution of infection was described decades ago for younger adults ( 10 , 11 ). (cdc.gov)
  • Among all adults hospitalized with RSV, a large proportion are severely ill, as measured by the proportion admitted to the ICU and the proportion who died. (cdc.gov)